Full TitleLong-Term Quality of Life in Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors
Checkpoint inhibitors are immunotherapy drugs used to treat advanced melanoma and other cancers. They block the proteins that tumors use to evade detection by the immune system, enabling the immune system to find and destroy cancer cells. Examples include nivolumab, ipilimumab, and pembrolizumab.
However, checkpoint inhibitors can cause uncomfortable side effects. The goal of this study is to learn more about how these side effects impact long-term quality of life in people with metastatic melanoma treated with checkpoint inhibitors. Patients will take a survey questioning them about their overall quality of life, symptoms since starting immunotherapy, and any fatigue or negative financial impact they have experienced related to their cancer care. The survey can be completed through a secure website or over the phone.
- Patients must have been treated with checkpoint inhibitor therapy for metastatic melanoma.
- At least 1 year must have passed since the first dose of immunotherapy.
- Patients may not have received any other systemic therapy since beginning immunotherapy.
- Patients must have been diagnosed with metastatic melanoma at age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Deborah Korenstein at 646-888-8210.